Pharmaceutical Business Review |
Actavis, Adamas win FDA approval for Alzheimer's drug
Reuters (Reuters) – The U.S. Food and Drug Administration approved a drug to treat dementia in Alzheimer's patients that was developed by Actavis Plc and Adamas Pharmaceuticals Inc. Adamas shares were up nearly 17 percent at $17.10 in premarket trading. Actavis, Adamas Pharma Win FDA Approval For Alzheimer's Drug Namzaric |
